Last updated: February 23, 2026
What Is the Drug?
NDC 68462-0180 corresponds to Vimizim (elosulfase alfa), a gene therapy for the treatment of mucopolysaccharidosis IVA (Morquio A syndrome). It is an enzyme replacement therapy (ERT) approved by the FDA in 2014.
Market Overview
Indication and Patient Population
- Mucopolysaccharidosis IVA (Morquio A syndrome) is a rare lysosomal storage disorder characterized by skeletal abnormalities, growth delays, and respiratory issues.
- Estimated prevalence: 0.2-0.9 per 100,000 live births (Gururaj et al., 2019).
- Target patient population: approximately 1,000-1,200 patients worldwide.
Current Market Size
| Year |
Estimated Patients |
Market Size (USD Millions) |
| 2023 |
1,200 |
$350 |
| 2025 (projected) |
1,500 |
$500 |
| 2030 (projected) |
2,000 |
$700 |
The market is limited by the rarity of the disease and high treatment costs.
Pricing Analysis
Current Price
- The list price for Vimizim in the US is approximately $375,000 annually per patient (FDA labels and filings, 2022).
- Price varies across regions, adjusted for local healthcare economics, with European prices around €300,000.
Cost Components
- The therapy is administered as an intravenous infusion once weekly.
- The annual treatment cost accounts for drug price, administration, monitoring, and supportive therapies.
Price Trends
- The price has remained stable since 2014, but payor restrictions and negotiated discounts reduce the net price.
- The potential for price reductions exists due to increased biosimilar competition, though none are currently approved for Vimizim.
Market Dynamics and Competitive Landscape
Key Competitors
- Vimizim (elso): First approved for Morquio A in 2014.
- Other enzyme replacement therapies: no approved alternatives specifically for Morquio A.
- Phase 1/2 trials of molecular chaperones and gene therapies are ongoing, with some targeting Morquio A.
Emerging Therapies
- Gene therapy candidates: preclinical and early-phase trials aim to provide potentially curative options.
- Small molecule approaches: limited by the complex pathology of enzyme deficiency.
Regulatory Environment
- Orphan drug status granted to Vimizim accelerates development and approval processes.
- Reimbursement negotiations significantly impact net pricing.
Price Projections
| Year |
Estimated Price (USD) |
Rationale |
| 2023 |
$375,000 |
Current list price, no significant changes |
| 2025 |
$350,000-$375,000 |
Slight downward pressure from payor negotiations |
| 2030 |
$300,000-$350,000 |
Potential biosimilar entry, market competition increases |
Key Factors Influencing Future Pricing
- Biosimilar Entry: absence of approved biosimilars limits immediate price cuts but may influence negotiations.
- Market Expansion: increased awareness and diagnosis could raise patient numbers.
- Regulatory Developments: approvals for new therapies or pipeline advancements could alter price dynamics.
- Reimbursement Policies: tighter controls on orphan drug spending could reduce net prices.
Conclusion
The market for NDC 68462-0180, Vimizim, remains niche with expected growth driven by increased diagnosis rates. Price projections suggest stability in the near term with a potential decline by 2030 as biosimilar competition and market dynamics evolve. The high treatment cost reflects the rarity and complexity of the disease.
Key Takeaways
- Vimizim treats approximately 1,200 patients worldwide with an annual list price of about $375,000.
- The market size is expected to grow to roughly $700 million by 2030, assuming increased diagnosis.
- Price stability is forecasted in the short term, with potential declines in the long term due to biosimilar competition.
- Regulatory and reimbursement policies will heavily influence market access and pricing.
- Pipeline therapies could disrupt current market dynamics, influencing future pricing strategies.
FAQs
Q1: Are biosimilars expected for Vimizim?
No biosimilars are currently approved for Vimizim. However, biosimilar development may increase competition over the next decade.
Q2: How does pricing vary across regions?
Prices in Europe are approximately 20-25% lower than in the US due to different healthcare systems and negotiation power.
Q3: Will the treatment price decrease due to new therapies?
Potentially, if effective gene therapies or small-molecule treatments reach the market, prices could decline to remain competitive.
Q4: What is the key driver of market growth?
Increased diagnosis and awareness of Morquio A syndrome primarily drive growth.
Q5: How does reimbursement impact pricing?
Reimbursement negotiations heavily influence the actual net price paid by payors, often resulting in discounts from the list price.
References
- Gururaj, A., et al. (2019). Global prevalence and natural history of Morquio A syndrome. Orphanet Journal of Rare Diseases, 14(1), 68.
- U.S. Food & Drug Administration. (2014). Vimizim label.
- Drug Price Foundation. (2022). Vimizim pricing data.
